BR112015029658A2 - produto farmacêutico, kit, método de tratamento e combinações - Google Patents

produto farmacêutico, kit, método de tratamento e combinações

Info

Publication number
BR112015029658A2
BR112015029658A2 BR112015029658A BR112015029658A BR112015029658A2 BR 112015029658 A2 BR112015029658 A2 BR 112015029658A2 BR 112015029658 A BR112015029658 A BR 112015029658A BR 112015029658 A BR112015029658 A BR 112015029658A BR 112015029658 A2 BR112015029658 A2 BR 112015029658A2
Authority
BR
Brazil
Prior art keywords
kit
combinations
treatment method
pharmaceutical product
product
Prior art date
Application number
BR112015029658A
Other languages
English (en)
Inventor
Higgins Brian
Nichols Gwen
E Packman Kathryn
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR112015029658A2 publication Critical patent/BR112015029658A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

resumo “produto farmacêutico, kit, método de tratamento e combinações” são providos produtos farmacêuticos compreendendo a) um primeiro componente compreendendo o composto de formula (a); e b) um segundo componente compreendendo capecitabina para o tratamento simultâneo ou sequencial de câncer, kits compreendendo dito produto assim como métodos para o tratamento de pacientes com câncer pela administração de dito produto.
BR112015029658A 2013-06-19 2014-06-16 produto farmacêutico, kit, método de tratamento e combinações BR112015029658A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361836894P 2013-06-19 2013-06-19
PCT/EP2014/062490 WO2014202492A1 (en) 2013-06-19 2014-06-16 Combination of ro5503781 and capecitabine for cancer therapy

Publications (1)

Publication Number Publication Date
BR112015029658A2 true BR112015029658A2 (pt) 2017-07-25

Family

ID=50981495

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015029658A BR112015029658A2 (pt) 2013-06-19 2014-06-16 produto farmacêutico, kit, método de tratamento e combinações

Country Status (14)

Country Link
US (1) US20160129033A1 (pt)
EP (1) EP3010513B1 (pt)
JP (1) JP6239745B2 (pt)
KR (1) KR20160007662A (pt)
CN (1) CN105307660A (pt)
BR (1) BR112015029658A2 (pt)
CA (1) CA2912816A1 (pt)
ES (1) ES2741003T3 (pt)
HK (1) HK1214502A1 (pt)
MX (1) MX2015016893A (pt)
PL (1) PL3010513T3 (pt)
RU (1) RU2015152577A (pt)
TR (1) TR201910701T4 (pt)
WO (1) WO2014202492A1 (pt)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050227932A1 (en) * 2002-11-13 2005-10-13 Tianbao Lu Combinational therapy involving a small molecule inhibitor of the MDM2: p53 interaction
US8232298B2 (en) * 2006-03-22 2012-07-31 Janssen Pharmaceutica N.V. Inhibitors of the interaction between MDM2 and P53
ES2431564T3 (es) * 2006-03-22 2013-11-27 Janssen Pharmaceutica N.V. Inhibidores de la interacción entre MDM2 y p53
WO2008034039A2 (en) * 2006-09-15 2008-03-20 Nexuspharma Inc. Novel tetrahydro-isoquinolines
JP5053674B2 (ja) * 2007-03-26 2012-10-17 テルモ株式会社 耳式体温計
AU2009279771B2 (en) * 2008-08-04 2015-05-14 Wyeth Llc Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine
US8354444B2 (en) * 2008-09-18 2013-01-15 Hoffmann-La Roche Inc. Substituted pyrrolidine-2-carboxamides

Also Published As

Publication number Publication date
HK1214502A1 (zh) 2016-07-29
TR201910701T4 (tr) 2019-08-21
PL3010513T3 (pl) 2019-11-29
WO2014202492A1 (en) 2014-12-24
US20160129033A1 (en) 2016-05-12
CA2912816A1 (en) 2014-12-24
RU2015152577A (ru) 2017-07-24
ES2741003T3 (es) 2020-02-07
JP2016522228A (ja) 2016-07-28
CN105307660A (zh) 2016-02-03
MX2015016893A (es) 2016-04-07
EP3010513B1 (en) 2019-06-05
JP6239745B2 (ja) 2017-11-29
KR20160007662A (ko) 2016-01-20
EP3010513A1 (en) 2016-04-27

Similar Documents

Publication Publication Date Title
BR112016009669A8 (pt) produtos farmacêuticos, método para tratar câncer e uso de um composto
EA201600204A1 (ru) Производные хиназолина, фармацевтическая композиция на их основе и их применение для профилактики или лечения опухоли
BR112015026023A2 (pt) derivados de 2- aminopirido[4,3-d]pirimidin-5-ona e seu uso como inibidores de wee-1
BR112015026006A2 (pt) métodos para o tratamento de câncer com o uso de terapia de combinação com inibidor de cinase tor
MY198613A (en) Nitrobenzyl derivatives of anti-cancer agents
EA201891063A1 (ru) Производные дигидроимидазопиразинона, применимые в лечении рака
BR112015026297A2 (pt) terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer
MX2016015434A (es) Combinaciones farmaceuticas para tratar cancer.
BR112017026535A2 (pt) composto de fórmula estrutural i, enantiômero isolado, composição farmacêutica, método para inibir atividade do transportador de monocarboxilato mct4, método para inibir seletivamente atividade do transportador de monocarboxilato mct4, método para tratar um distúrbio mediado por transportador de monocarboxilato mct4 e uso de um composto
TR201901077T4 (tr) Kanser Veya Enfeksiyon Tedavisine Yönelik Birleşik Preparasyonlar
CL2015003343A1 (es) Composición farmacéutica que comprende un agente terapéutico modificado en base a hemoglobina, para el tratamiento para tratar el cáncer, e imágenes de diagnóstico.
BR112018068412A2 (pt) composto, composição farmacêutica, método de tratamento de síndrome mielodisplásica e método para matar uma célula tumoral
CL2015000039A1 (es) Derivados estra-1,3,5(10),16-tetraeno-3-sustituidos, preparaciones farmacéuticas que los comprenden y su uso en la preparación de medicamentos para tratar la endometriosis.
AR092899A1 (es) Uso de masitinib para el tratamiento del cancer en subpoblaciones de pacientes identificados que utilizan factores de prediccion
BR112017003433A2 (pt) inibidores espirocíclicos de catepsina c
PH12016502352A1 (en) Pharmaceutical composition
BR112017004589A2 (pt) composto, composição farmacêutica, método para tratar um paciente, uso de um composto, kit, e método para tratar um distúrbio mediado por proteína smyd
BR112017009552A8 (pt) Métodos para alvejar o controle transcricional em regiões de super-realçador
EA201591024A1 (ru) Димерные соединения
MX2016015762A (es) Derivados de alquilo y arilo de compuestos de 1-oxa-4,9-diazaspiro undecano que tienen actividad multimodal contra el dolor.
TW201613578A (en) Pharmaceutical combinations
TR201910866T4 (tr) Kanser tedavisi için birleşik preparasyonlar.
BR112017006113A8 (pt) usos de auristatina, composições farmacêuticas, formas de dosagem para o tratamento de câncer e kits.
DOP2017000244A (es) Derivados de pirazol útiles como inhibidores de proteína activadora de 5-lipoxigenasa (flap)
BR112016029012A2 (pt) método de tratamento de câncer de pulmão de células não pequenas e/ou câncer de pulmão de células pequenas usando compostos de tienotriazolodiazepina

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2518 DE 09-04-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B350 Update of information on the portal [chapter 15.35 patent gazette]